ArticleCureus2025
Assessment of the Clinical Efficacy and Safety of Azithromycin in Patients With Moderate to Severe Upper Respiratory Tract Infections (URTIs): Insights From an Indian Real-World Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Upper respiratory tract infections (URTIs) are commonly encountered in primary care. Azithromycin has emerged as a preferred therapy for URTIs due to its once-daily dosing, low resistance risk, and favorable gastrointestinal tolerability. This study evaluated the real-world effectiveness and safety of azithromycin (500 mg/day) in moderate to severe acute URTIs. Materials and methods This subgroup analysis of a retrospective, multicenter, observational study analyzed data from 184 ENT centers in India over 12 weeks. Medical records of adult patients with moderate to severe URTIs treated with azithromycin 500 mg daily for five days were included. Key clinical signs (pharyngeal and tonsillar erythema, exudates) and symptoms (sore throat, fever, daily activity interference) were assessed on a 3-point scale. Treatment effectiveness was evaluated through changes in cumulative symptom scores and Clinical Global Impression scores on day 5. Data were analyzed using paired t-tests and McNemar-Bowker tests, with p<0.05 indicating significance. Ethical approval was obtained, and all data collection adhered to Good Clinical Practice standards. Results Data from 427 patients with moderate to severe URTIs were analyzed. By day 5, significant improvements were observed across all clinical parameters. Proportion of patients with moderate pharyngeal erythema (40.7%) and severe cases (59.3%) reduced significantly to 16.6% and 0.2%, respectively, and severe tonsillar erythema (63%) reduced from baseline to no cases with severe tonsillar erythema at day 5. Tonsillar exudates reduced from 52.9% to 7.6% for moderate cases and from 47.1% to 0.2% for severe cases. Sore throat severity dropped from 73.5% to only 0.2% reporting difficulty swallowing. Fever resolved in 96.7% of patients, and work absenteeism reduced from 71.2% to 0.9%. Clinical Global Impression scores indicated improvement in 90% of patients. Adverse events were reported in only 2.1% of cases. Conclusion Azithromycin demonstrated significant clinical effectiveness in managing moderate to severe URTIs, with marked improvements in key symptoms and signs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.